Real-world data firm Litmus Health published its first census of wearable devices for clinical research.
The FIX-Padua therapy achieved FIX activity levels of 23% to 37%, suggesting it is several times more effective than unIQure's old asset.
In 1848, the most famous Gold Rush in American history began at Sutter's Mill near present-day Coloma, California, shaping the US economic map forever. In…
The dermatology-focused Roivant subsidiary has hired Zavodnick to fill the role vacated by Jackie Fouse in September.
Cadent Therapeutics is coming out of stealth with a new CMO and $40 million to move its ion channel modulator programs into phase 2.
Nektar Therapeutics poached Genentech immunotherapy leader Wei Lin to head up its oncology program and serve as VP of clinical development.
UB-312 prevented the accumulation of misfolded alpha-synuclein proteins in cell and animal models of Parkinson's disease.
Respiratory care specialist Vapotherm raised $56 million in an IPO on the New York Stock Exchange under the symbol VAPO.
Celgene is doubling down on its cancer immunotherapy pact with Dragonfly Therapeutics, paying $50 million for access to four more natural killer (NK) cell-…
Lilly is seeking approval of the 5-HT1F agonist on the strength of late-phase data showing the drug can clear headache pain in two hours.
Synthorx wants a $100 million IPO, but is the window closing?